Celiac Panel Sex- and Cycle-Related Differences: What Your Results Actually Mean

Why Sex and Hormones Matter for Celiac Serology

Women are diagnosed with celiac disease at roughly twice the rate of men in most clinical series, yet population-based screening data show a narrower sex gap. The discrepancy points to hormonal and immune factors that lower the diagnostic threshold in women rather than a simple difference in underlying prevalence. A 2020 meta-analysis of 26 population studies (N = 215,000+) reported a pooled female-to-male odds ratio of 1.83 (95% CI 1.62 to 2.06) for biopsy-confirmed celiac disease, a figure that climbs further in reproductive-age cohorts 1.

Sex hormones modulate mucosal immunity at multiple levels. Estrogen receptor alpha (ERα) is expressed on intestinal epithelial cells and on lamina propria B cells, where its activation promotes IgA class switching. Testosterone, by contrast, has a net anti-inflammatory effect on T-helper cell activity that may dampen the anti-gliadin response. These are not trivial distinctions when interpreting a tTG-IgA result that sits just above the laboratory reference range.

How Estrogen Shifts IgA Production

Estradiol at mid-follicular concentrations (roughly 100 to 200 pg/mL) increases transcription of the cytokine APRIL (a proliferation-inducing ligand), which drives plasma cell differentiation and IgA secretion in mucosal tissue 2. A premenopausal woman in the late follicular phase may therefore carry a modestly higher baseline serum IgA than the same woman in the early luteal phase. Because tTG-IgA is an IgA-class antibody, even small fluctuations in total IgA output can nudge the tTG-IgA value across a reference-range boundary.

Practically, this means a borderline tTG-IgA result (1 to 2x the upper limit of normal) drawn at mid-cycle in a woman with high estradiol deserves a confirmatory retest. Retesting in the early follicular phase (days 2 to 5) when estradiol is at its nadir provides a cleaner baseline.

Testosterone and the Male Antibody Profile

Men with untreated celiac disease present with lower median tTG-IgA titers than women at the same villous-atrophy Marsh grade, a pattern documented in a 2018 Italian multicenter cohort (N = 1,247) 3. One proposed mechanism: testosterone suppresses Th17 polarization in the small bowel lamina propria, reducing IL-17-driven mucosal permeability and consequently reducing antigen load available to drive antibody production. This does not make celiac disease less damaging in men. It makes serology less sensitive. Men with unexplained iron-deficiency anemia or low-B12 should have a celiac panel regardless of titer magnitude.

Components of a Standard Celiac Panel

A complete celiac panel ordered in 2025 typically includes four analytes. Each behaves differently across the hormonal milieu.

tTG-IgA (Tissue Transglutaminase IgA)

TTG-IgA is the first-line marker endorsed by the American College of Gastroenterology (ACG) 2023 guidelines, which state: "tTG-IgA has sensitivity of 95% and specificity of 98% for active celiac disease in IgA-sufficient adults" 4. Most commercial platforms define the upper limit of normal at either 4 U/mL or 10 U/mL. A value above 10x the ULN has a positive predictive value approaching 98% for Marsh 3 villous atrophy, high enough that the European Society for Paediatric Gastroenterology (ESPGHAN) 2020 guidelines allow biopsy to be omitted in children with titers above that threshold combined with a positive EMA 5.

In women on combined oral contraceptives (COCs), synthetic estrogen (ethinyl estradiol) at 20 to 35 mcg doses maintains a relatively stable, low-estrogen environment compared to natural mid-cycle peaks. Total serum IgA is typically lower in COC users than in naturally cycling women at the same cycle day, which may slightly attenuate tTG-IgA values and increase the risk of a false-negative in women with mild villous injury.

EMA-IgA (Endomysial Antibody IgA)

EMA-IgA is highly specific (greater than 99%) but less sensitive (85 to 90%) and is performed by immunofluorescence, making it operator-dependent. ACG 2023 recommends EMA-IgA as a confirmatory test when tTG-IgA is equivocal 4. EMA-IgA follows total IgA flux similarly to tTG-IgA, so the same cycle-phase cautions apply.

DGP-IgG (Deamidated Gliadin Peptide IgG)

DGP-IgG becomes the primary screening marker when total serum IgA is below 7 mg/dL (selective IgA deficiency). IgA deficiency occurs in 2 to 3% of celiac patients versus 0.2% of the general population, so checking total IgA simultaneously with tTG-IgA is standard practice 6. DGP-IgG is less susceptible to cycle-phase fluctuation because IgG class switching depends less on APRIL-driven estrogen signaling. Women with known hypogammaglobulinemia or IgA deficiency should always have DGP-IgG as part of their panel.

Total Serum IgA

Total IgA serves as a quality-control analyte. Reference ranges are 70 to 400 mg/dL in adults. Values below 7 mg/dL invalidate IgA-based markers and mandate IgG-class substitution. Because estrogen upregulates IgA production, postmenopausal women off hormone therapy may drift toward the lower half of the reference range, subtly reducing sensitivity of tTG-IgA assays.

Optimal Celiac Panel Ranges: What "Normal" Misses

Standard laboratory reports flag values as "positive" or "negative" against a population-derived cutoff. Longevity-medicine and functional practitioners increasingly look at where within the reference range a value sits. For celiac serology, several tier thresholds carry clinical meaning.

The 10x ULN Rule

A tTG-IgA above 10 times the upper limit of normal is near-diagnostic. A value between 1x and 3x ULN on a gluten-containing diet warrants confirmatory testing, not dismissal. The ACG 2023 guideline is explicit: "Mildly elevated tTG-IgA (1 to 3× ULN) requires EMA-IgA or HLA-DQ2/DQ8 genotyping before proceeding to endoscopy" 4.

Monitoring After Gluten-Free Diet

On a strict gluten-free diet (GFD), tTG-IgA should fall by at least 50% within 6 months and normalize (below ULN) within 12 to 24 months in most adults 7. A tTG-IgA that fails to fall by 50% at 6 months on a declared GFD should prompt a dietitian assessment for hidden gluten exposure before concluding treatment failure. Women in the perimenopausal transition who start hormone therapy may see a transient mild rise in tTG-IgA due to estrogen-driven IgA upregulation even without gluten re-exposure. This is a documented, if underappreciated, confound.

DGP-IgA and DGP-IgG as Sensitivity Boosters

Some panels include both DGP-IgA and DGP-IgG. A 2019 systematic review (N = 5,765) found that adding DGP-IgG to tTG-IgA raised sensitivity from 95% to 97.3% for Marsh 2 to 3 lesions, with only a marginal specificity cost 8.

Celiac Disease and the Female Endocrine Axis

The relationship between celiac disease and female hormonal health runs in both directions. Untreated celiac disrupts nutrient absorption in ways that impair steroidogenesis, and sex hormones in turn modulate antibody titers on the celiac panel.

Iron, B12, and Reproductive Hormones

The proximal small bowel (duodenum and jejunum) absorbs both iron and vitamin B12 (the latter via intrinsic-factor-dependent mechanisms in the terminal ileum). Villous atrophy from untreated celiac flattens the absorptive surface at both sites. In premenopausal women, monthly menstrual blood loss of 30 to 80 mL already stresses iron stores; combined with malabsorption, iron-deficiency anemia becomes near-universal in untreated celiac in this demographic. A 2017 UK Biobank analysis found that premenopausal women with undiagnosed celiac had a 3.4-fold higher odds of ferritin below 15 mcg/L compared to matched controls 9.

Low iron and B12 depress erythropoiesis and impair thyroid hormone synthesis (thyroid peroxidase is an iron-dependent enzyme). This creates a compounding hormonal deficit that looks clinically like hypothyroidism but may not fully respond to levothyroxine until celiac is treated and gut absorption is restored.

Thyroid Autoimmunity Overlap

Up to 30% of patients with Hashimoto thyroiditis carry positive tTG-IgA or EMA-IgA at low titer 10. The ACG 2023 guideline lists autoimmune thyroid disease as an indication for celiac screening even in asymptomatic patients 4. Given that Hashimoto's occurs 7 to 10 times more often in women than men, a comprehensive thyroid workup in women should reflexively include a celiac panel, particularly if TSH is elevated despite adequate levothyroxine dosing.

Pregnancy and Third-Trimester False Negatives

Pregnancy shifts the maternal immune system toward Th2 and regulatory T-cell (Treg) dominance to prevent fetal rejection. This immune tolerance phenotype can suppress tTG-IgA titers even in women with active villous atrophy, producing false-negative celiac panels in the third trimester. A small prospective study (N = 43 pregnant women with biopsy-confirmed celiac on a gluten-containing diet) found that 14% had tTG-IgA values below the assay ULN in the third trimester that rebounded to positive levels within 6 weeks postpartum 11. Clinicians ordering celiac panels during pregnancy should note gestational age on the requisition and consider retesting postpartum if clinical suspicion remains.

Menopause, HRT, and Serology

In postmenopause, declining estradiol reduces IgA class switching. Women transitioning off estrogen-dominant HRT may see tTG-IgA fall even without dietary change. Conversely, starting transdermal estradiol at 50 to 100 mcg/day in a postmenopausal woman with previously negative celiac serology could unmask a borderline elevation that reflects true low-grade mucosal injury rather than a hormone-driven false positive. Retesting 3 months after any significant hormonal change captures this drift.

Sex-Specific Celiac Complications That Affect Lab Ordering

Reproductive Failure and Celiac Antibodies

Recurrent pregnancy loss (RPL, defined as two or more consecutive losses) is associated with untreated celiac in several cohort studies. A 2016 meta-analysis (N = 24 studies) found a pooled odds ratio of 1.39 (95% CI 1.03 to 1.88) for RPL in women with celiac compared to controls, with the risk attenuating significantly after adoption of a gluten-free diet 12. Women presenting with RPL without an identified cause should have a full celiac panel.

Osteoporosis Screening Cascade

Malabsorption of calcium and vitamin D from untreated celiac accelerates bone loss. The National Osteoporosis Foundation and ACG both recommend DXA scanning at diagnosis of celiac disease regardless of age. Low bone density in a premenopausal woman should trigger celiac serology as part of the workup, alongside 25-OH vitamin D and PTH.

Testosterone and Male Celiac Workup

Men with low serum testosterone (below 300 ng/dL), reduced libido, or unexplained fatigue alongside iron-deficiency anemia should have celiac serology included in their workup. Chronic mucosal inflammation from untreated celiac elevates TNF-alpha, which suppresses LH pulsatility and secondary testosterone production. Correction of the underlying gut pathology can raise testosterone by 30 to 60 ng/dL in some men without any exogenous androgen.

When to Order a Celiac Panel: Clinical Triggers by Sex

The following framework summarizes sex-specific indications for celiac panel ordering, derived from ACG 2023 4 and the British Society of Gastroenterology 2014 guidelines 13, with hormonal context layered in.

Women: order a celiac panel when any of the following apply.

• Iron-deficiency anemia not explained by menstrual loss alone (ferritin <15 mcg/L with normal menses or ferritin <10 mcg/L in general), particularly if MCV is low.
• Hashimoto's thyroiditis or TSH persistently above 4.5 mIU/L despite optimized levothyroxine dosing.
• Two or more consecutive pregnancy losses with no identified cause.
• Premature ovarian insufficiency (POI) before age 40 without chromosomal cause.
• First-degree relative with confirmed celiac disease (10% lifetime risk).
• Unexplained low bone density (T-score <-1.0) in a woman under 50 on a normal diet.

Men: order a celiac panel when any of the following apply.

• Iron-deficiency anemia in any man (no physiologic reason for iron loss).
• Combined low-B12 and low ferritin without a dietary or medication explanation.
• Testosterone below 300 ng/dL with elevated inflammatory markers (hsCRP above 3 mg/L) and no other explanation.
• Autoimmune thyroid disease.
• First-degree relative with confirmed celiac.
• Unexplained diarrhea or steatorrhea lasting more than 4 weeks.

Cycle-phase guidance for borderline results.

Retest borderline tTG-IgA (1 to 3x ULN) in naturally cycling women during days 2 to 5 of the menstrual cycle, when estradiol is at nadir. If the woman is on hormonal contraception, retest timing matters less, but note the COC formulation on the lab requisition.

Interpreting Results in the Context of HRT and GLP-1 Agonists

Semaglutide (Ozempic, Wegovy) and other GLP-1 receptor agonists slow gastric emptying and alter small-bowel transit time. No large trial has yet reported a systematic effect on celiac antibody titers, but delayed gastric emptying reduces the rate of gliadin peptide presentation to the proximal intestinal mucosa. Theoretically, this could mildly attenuate tTG-IgA in patients on GLP-1 agonists who are not on a GFD. Until data emerge, note GLP-1 agonist use on the lab requisition when ordering celiac panels.

Women on estrogen-based HRT (oral estradiol or combined estrogen-progestogen therapy) who have a personal or family history of celiac should have a baseline celiac panel before starting HRT and a retest at 6 months. Oral estradiol at 1 to 2 mg/day raises total IgA measurably in some women, a fact confirmed in a randomized crossover study comparing oral versus transdermal estradiol 14. Transdermal estradiol produces smaller fluctuations in mucosal IgA and may be the preferable route in women with borderline celiac serology.

The ACG 2023 guideline recommends: "Clinicians should be aware that immunomodulatory medications including corticosteroids and other immune suppressants can reduce tTG-IgA titers and may produce false-negative results in patients with active celiac disease" 4. Exogenous estrogen belongs in a similar category of immune modulators, though the effect size is smaller.

Practical Retesting Schedule

After a new celiac diagnosis confirmed by biopsy, follow-up celiac panel timing should account for sex and hormonal status.

For premenopausal women on no hormonal therapy: retest tTG-IgA at 6 months (early follicular phase, days 2 to 5) and again at 12 months. A 50% drop at 6 months and normalization by 12 to 24 months confirms dietary adherence.

For women on COC or HRT: retest at 6 months on the same phase of the pill cycle each time (e.g., always during the pill-free interval for COC users) to reduce inter-test variability.

For men: no cycle-phase constraint exists. Retest at 6 and 12 months on a GFD. Men tend to normalize tTG-IgA more slowly than women despite equivalent dietary adherence, possibly because testosterone-related reduction in initial antibody magnitude makes percent-change calculations less reliable as a compliance marker.

For pregnant women with known celiac on a GFD: skip routine celiac serology in the third trimester. The false-negative rate is high enough to make a negative result uninformative. Retest at 6 weeks postpartum instead.